BioPharma Today

Season's Greetings From BioPharma Today!

Happy Holidays

In the spirit of the season, BioPharma Today will not be posting new content on December 30.

We will resume new posts starting January 6, 2009. We wish all our readers a joyful holiday season and all the best for 2009.

2008 In Review: China’s Major Legal & Regulatory Changes For Healthcare Sector

Full article reprinted from PharmAsia News December 23, 2008

In a review of the major legal and regulatory measures that changed China's healthcare landscape in 2008, Chinese and European lawyers stated the merger of the State FDA into the Ministry of Health is likely to have the most significant impact into the future. Find out why...

The A-List: 2007's Trend Shaping Series A Financings

Article preview from Start-Up December 23, 2008

In 2007, what did Series A venture investments reveal about the state of the health care industry? It was very healthy, thank you. There were quite a few deals to choose from, and numbers demonstrated continued growth in diagnostics fundraising, a resurgence in vaccines, and evidence of pharma's interest in proof-of-concept projects and large-molecule platforms. Read more...

Economic Forecast for Pharma: Winter Weather Advisory Ahead

Article preview from "IN VIVO" December 23, 2008

Pharma has weathered its share of economic downturns, but the data shows that the industry could be in for a tough winter. Prolonged cutbacks by consumers failing to refill prescriptions in tough economic times could become yet another obstacle for drug manufacturers already facing plenty of challenges in the coming year in the form of patent expirations, lackluster pipelines and stricter regulatory oversight. Find out more...

Special Annoucement: The IN VIVO Blog Wants you to Particapate in a Special Vote

It's time to have your say, The IN VIVO Blog wants readers to particapate in a poll for the Deal of the Year. This feature is live now! Please vote.

Get your friends and colleagues and families to vote. Click here to access the voting poll.

Merck Outlines Plans For 2009 NDA Filings; Migraine Drug Is Best Bet

Full Article reprinted from "The Pink Sheet" December 23, 2008

Merck's fledgling bioventures business may have dominated headlines following the company's recent analyst day, but the firm's other initiatives are likely to contribute more to near-term growth as Merck tries to address the revenue gap that will be left by key patent expirations in the next few years. Read more...

Introducing BioPharma Today's Sister Site: Over The Counter Today

 

FDC-Windhover, publishers of "The Tan Sheet" and “The Rose Sheet”, is pleased to announce the launch of Over The Counter Today (www.OverTheCounterToday.com), a new free beta site featuring exclusive analysis of the consumer health industry, including nonprescription drugs, nutritionals, cosmetics and toiletries.

In addition to visiting the website, readers can sign up to receive a free weekly email newsletter.

Rep. Stark Sees Health Reform Votes In Late 2009/Early 2010, “Deferred Maintenance” Items Sooner

Full preview from "The Pink Sheet" DAILY December 23, 2008

House Ways and Means Health Subcommittee Chairman Pete Stark, D-Calif., is predicting that any congressional votes on comprehensive health care reform legislation will take place toward the end of 2009 or, at the latest, early the following year. Find out why...

Prioritizing Health Care: Reform Gains Early Momentum

Article reprinted from "The RPM Report" December 23, 2008

Find out why Health care reform advocates think the stars are aligned for a major push toward universal coverage under President-elect Barack Obama. They aren’t about to let the free-falling economy get in the way.

Death Vs. Symptomatic Relief – Weighing Risks And Benefits For Asthma Drugs

Article preview from "The Pink Sheet" December 23, 2008

When discussing a drug's benefits and risks, there is more to the equation than just death, Judith Kramer, Duke University, pointed out during a meeting of three FDA advisory committees to discuss asthma indications for long-acting beta agonists. Read more now...